Torres Lidiane de Souza, Okumura Jéssika Viviani, da Silva Danilo Grünig Humberto, Belini Júnior Édis, de Oliveira Renan Garcia, Mimura Kallyne Kioko Oliveira, Lobo Clarisse Lopes de Castro, Oliani Sonia Maria, Bonini Domingos Claudia Regina
Laboratory of Hemoglobin and Hematologic Genetic Diseases, Department of Biology, Sao Paulo State University (Unesp), Rua Cristóvão Colombo, 2265, São Jose do Rio Preto, SP 15054-000, Brazil.
Laboratory of Hemoglobin and Hematologic Genetic Diseases, Department of Biology, Sao Paulo State University (Unesp), Rua Cristóvão Colombo, 2265, São Jose do Rio Preto, SP 15054-000, Brazil.
Cytokine. 2016 Apr;80:18-25. doi: 10.1016/j.cyto.2016.02.012. Epub 2016 Feb 27.
Sickle cell disease (SCD) represents a chronic inflammatory condition with complications triggered by the polymerization of hemoglobin S (Hb S), resulting in a series of cellular interactions mediated by inflammatory cytokines, as the transforming growth factor beta (TGF-β), which plays an important role in inflammation resolution. This study assessed the relation between SCD inflammation and the plasma concentration of TGF-β1, and also checked the influence of the presence of -509C/T polymorphism in TGFB1 gene on TGF-β1 plasma values. The plasma levels of TGF-β1 were quantified by ELISA in 115 patients with SCD (genotypes SS, SD-Los Angeles, Sβ-thalassemia and SC) and in 58 individuals with no hemoglobinopathies (Hb AA), as the control group. The -509C/T polymorphism in TGFB1 gene was screened by PCR-RFLP. The correlation between TGF-β1 plasma levels and the inflammation was based on its association with the count of platelets, total white blood cells (WBC) and neutrophils in the peripheral blood. Patients with SCD showed plasma levels of TGF-β1 higher than the control group, especially the Hb SS genotype, followed by the group with Hb SD. Polymorphism investigation showed no interference in the values obtained for the cytokine in the groups evaluated. All SCD groups showed TGF-β1 levels positively correlated to the platelets and WBC counts. The original data obtained in this study for SCD support the involvement of TGF-β1 in regulating of the inflammatory response and suggest that this marker possibly may become a potential therapeutic target in the treatment of the disease.
镰状细胞病（SCD）是一种慢性炎症性疾病，由血红蛋白S（Hb S）聚合引发并发症，导致一系列由炎症细胞因子介导的细胞相互作用，如转化生长因子β（TGF-β），其在炎症消退中起重要作用。本研究评估了SCD炎症与TGF-β1血浆浓度之间的关系，并检测了TGFB1基因中-509C/T多态性的存在对TGF-β1血浆值的影响。通过酶联免疫吸附测定法（ELISA）对115例SCD患者（基因型为SS、SD-洛杉矶型、Sβ地中海贫血和SC）和58例无血红蛋白病的个体（Hb AA）作为对照组进行TGF-β1血浆水平定量。通过聚合酶链反应-限制性片段长度多态性（PCR-RFLP）筛选TGFB1基因中的-509C/T多态性。TGF-β1血浆水平与炎症之间的相关性基于其与外周血中血小板计数、总白细胞（WBC）和中性粒细胞的关联。SCD患者的TGF-β1血浆水平高于对照组，尤其是Hb SS基因型，其次是Hb SD组。多态性研究表明，在所评估的组中，该多态性对细胞因子的值没有干扰。所有SCD组的TGF-β1水平均与血小板和WBC计数呈正相关。本研究中获得的SCD原始数据支持TGF-β1参与调节炎症反应，并表明该标志物可能成为该疾病治疗的潜在靶点。
